BOSTON (TheStreet) -- I've long warned investors to be wary of companies that use dubious scientific analysis to spin positive results from what are really failed clinical trials.
Call it post-hoc data mining or retrospective data dredging, but by either name, the purpose of these all-too-common tactics is usually to deflect investors' attention away from bad news.
Apricus Biosciences (APRI) and Cel-Sci (CVM) issued separate press releases in the past week which relied heavily on post-hoc data mining to hype the prospects of experimental -- and deeply flawed -- drugs in their respective pipelines. Knowing how to spot the red flags in these types of announcements can save you a lot of pain and losses down the road.
The headline on Apricus' announcement set off alarm bells immediately: "Apricus Biosciences Reports Reanalysis of Its U.S. Phase III Trials for MycoVa Showing Drug is Effective in Mycological Cure Resulting in Eradication of Nail Fungus." [Emphasis mine.]Re-analysis? What happened to the first analysis of the phase III trials of MycoVa? Apricus doesn't say, but Google and SEC filings are a big help. In August 2008, Apricus (then known as NexMed) announced that its partner Novartis decided against seeking U.S. approval for MycoVa (then known as NM100060) based on disappointing results from two double blind, placebo-controlled phase III clinical trials. One year later, in July 2009, Apricus/NexMed announced that Novartis was terminating its partnership for NM100060/MycoVa based on results from a third phase III study which compared MycoVa to Loceryl, a topical nail laquer marketed in Europe. This European phase III study failed although Apricus was spinning the results even back then, claiming that a "post hoc" analysis showed MycoVa worked better than Loceryl in patients with mild toenail fungus. Unfortunately for Apricus, the study enrolled patients with mild and moderate toenail fungus. Three failed phase III studies, one dropped Big Pharma partnership and two years later, Apricus is trying to convince investors that there's life left in MycoVa. This time, Apricus claims that a re-analysis of the two U.S. clinical trials found MycoVa cures toenail fungus better than placebo in patients who do not also have athlete's foot.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV